The sale is de minimis and likely a personal estate planning matter. No material impact on the stock is expected. Monitor for any larger insider sales or changes in officer holdings in future filings.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $902.90entry
- T+1 · 11d ago +0.16%α −0.15% · $904.35
- T+5 · 5d ago +5.35%α +2.06% · $951.19
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jason Pitofsky, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 180 shares of common stock, with an approximate market value of $175,205 based on the filing price. The shares were inherited and are being sold by Stephanie Pitofsky. This is a very small sale relative to the company's $99.4B market cap and the officer's likely holdings, making it a routine administrative filing.
Key Facts
- Jason Pitofsky, an officer of Regeneron, filed Form 144 to sell 180 shares of common stock.
- The estimated value of the proposed sale is $175,204.80 based on the filing price.
- Shares were acquired on 08/13/2024 via inheritance from Freddy Runne.
- The sale is to be executed by Stephanie Pitofsky through J.P. Morgan Securities LLC.
- The filing date is 2026-11-04.
Financial Impact
Proposed sale of 180 shares valued at approximately $175,205, which is negligible relative to the company's $99.4B market cap.
Risk Factors
- Form 144 is only an intent to sell; the actual sale may not occur.
- No additional context on the officer's total holdings is provided, so the proportional impact cannot be fully assessed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001968582-26-001101 |
| Document: 0001968582-26-001101-index.html | 0001968582-26-001101 |
| Document: 0001968582-26-001101.txt | 0001968582-26-001101 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Viewing Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers